new immune therapy phase 1-2 trial: targeting NK cells

[Maxone73]

The first patient with metastatic castration-resistant prostate cancer (mCRPC) has been dosed in the phase 1/2 CaRe PC trial (NCT06056791) evaluating INKmune, a biologic therapy

targetedonc.com/view/first-...

[bryson43]

I am having immunotherapy for kidney cancer for 12 months and working very well I appear to be getting a benefit from my stage 4 prostate cancer and my psa is only 0.04 after 18 years

Might be coincidental but I am not complaining

[Maxone73 in reply to bryson43]

Great news! Do you know what immunotherapy you are on?

[bryson43 in reply to Maxone73]

Ipi and nivo infusions

[Maxone73 in reply to bryson43]

probably not coincidental...

"Lastly, since the subgroup of AR-V7 positive patients has been associated with DDR genes mutations [68] and nivolumab plus ipilimumab showed encouraging efficacy and a manageable safety profile in AR-V7 positive, DDR mutated mCRPCs, this subset is considered particularly promising in terms of response to immune checkpoint monoclonal antibodies [69]. More specifically, a phase II biomarker-driven trial suggested that AR-V7 positive patients with DDR mutations (BRCA2, ATM, MSH6, FANCM, FANCA, and POLH) treated with nivolumab plus ipilimumab presented a statistically significant benefit in terms of PFS (lack of progression ≥24 weeks) compared to AR-V7 positive, DDR negative subjects [69].

Taken together, all these data suggest that some subgroups of PC patients could benefit from immunotherapy [70]. These could include subjects with aggressive tumors (e.g., Gleason pattern 5, ductal histology, etc.), PCs harboring homologous recombination deficiency (HRD) mutations, the AR-V7 positive subgroup, and patients with biomarker of response to immune checkpoint monoclonal antibodies such as high TMB and dMMR [71]. Nonetheless, the overall modest activity of immune checkpoint monoclonal antibodies in PC deserves well-designed, tailor-made trials as well as better biomarkers to improve the predictive capacity to unveil responders. In fact, rather than a single biomarker, an approach based on the integration of different biomarkers could most likely help in improving the understanding of the role of immune checkpoint monoclonal antibodies in malignancies where immunotherapy has reported low ORRs, such as mCRPC."